IRVINE, Calif., November 15, 2025 — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting medical devices and treatment methods optimized for local skin characteristics and environmental conditions. The clinic is expected to commence operations by year-end in the Asok district of Bangkok.
SBC operates a network of over 250 clinics worldwide, welcoming more than 6 million patient visits annually. By combining SBC’s proven expertise in delivering high-quality and safe aesthetic medical services developed in Japan with BLEZ’s trusted local presence, the two companies aim to establish a solid foothold among Japanese expatriates in Thailand. Following validation of service demand and operational performance, SBC and BLEZ intend to expand patient acquisition to the broader Thai market and pursue incremental growth opportunities across ASEAN.
According to industry research*, Thailand’s aesthetic medicine market was valued at approximately USD 372.24 million in 2024 and is projected to grow to USD 1.118 billion by 2033. With a forecasted compound annual growth rate (CAGR) of 13.51% from 2025 to 2033, Thailand has cemented its global position as a hub for medical tourism. Despite a population of around 60,000 Japanese expatriates, there are limited clinics offering “Japanese-quality” aesthetic treatments, and fragmented small-scale operators contribute to inconsistent service quality. This creates significant opportunities for large, reliable medical groups to meet growing demand with safe and consistent care.
*Source: Astute Analytica, USA and Asia Pacific Aesthetic Medicine Market – Industry Dynamics, Market Size, and Opportunity Forecast to 2033, 2025 Edition
BLEZ, a Japanese-owned company with over 10 years of medical experience in Bangkok, operates a diverse portfolio including BLEZ Pharmacy, BLEZ Kampo Pharmacy, internal medicine, dentistry, and even veterinary hospitals. Its annual patient base reaches approximately 1,200 for clinics and 100,000 for pharmacies. BLEZ also engages in the import and sale of pharmaceuticals, supplements, and medical devices, OEM manufacturing, FDA registrations in Thailand, telemedicine, and franchise businesses. This extensive network and strong brand presence will provide powerful support for SBC’s market entry.
In November 2024, SBC launched operations in Singapore through a partnership with Aesthetic Healthcare Holdings (AHH). The new collaboration with BLEZ represents the next step in SBC’s ASEAN expansion, accelerating its growth strategy across the region. Beginning with the Japanese expatriate community, SBC will steadily build its business foundation, aiming to deliver consistently high-level medical services and establish new value in the Thai aesthetic medicine market.
Naoki Iida, CEO of BLEZ ASIA Co., Ltd.
“The Thai aesthetic medicine market continues to grow rapidly, with increasing focus on quality and safety. Partnering with SBC, a leader in Japan with outstanding expertise and proven track record, is an invaluable opportunity for BLEZ. By combining our strengths, we aim to firmly establish Japanese-standard, high-quality medical services in Thailand and build a brand that will be trusted and loved by the community for years to come.”
Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings, Inc.
“Japanese aesthetic medicine is globally competitive for its precision and high safety standards. SBC has been building its quality and reputation in Japan while preparing for global expansion. Partnering with a trusted local leader such as BLEZ in this fast-growing Thai market is a significant step forward in our Asia strategy. Together, we intend to create a model in which Japan’s advanced medical services can take root locally and deliver new value.”